CEL-SCI Corp CVM:NYSE American

Last Price$5.64AMEX Previous Close - Last Trade as of 6:30PM ET 1/21/22
AMEX 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$5.75 (5)
Ask (Size)$6.36 (41)
Day Low / HighN/A - N/A
Volume1.2 M
 

View Biotechnology IndustryPeer Comparison as of 01/21/2022

 

CEL-SCI Corp ( NYSE MKT LLC )

Price: $5.64
Change: -0.18 (3.09%)
Volume: 1.2 M
6:30PM ET 1/21/2022
 
 

Cymabay Therapeutics Inc ( NASDAQ )

Price: $2.89
Change: +0.10 (3.58%)
Volume: 2.0 M
4:00PM ET 1/21/2022
 
 

Pieris Pharmaceuticals Inc ( NASDAQ )

Price: $3.40
Change: +0.06 (1.80%)
Volume: 975.1 K
4:00PM ET 1/21/2022
 
 

Alpine Immune Sciences Inc ( NASDAQ )

Price: $8.40
Change: -0.07 (0.83%)
Volume: 147.3 K
4:00PM ET 1/21/2022
 
 

XOMA Corp ( NASDAQ )

Price: $21.34
Change: +0.45 (2.15%)
Volume: 44.4 K
4:00PM ET 1/21/2022
 

Read more news Recent News

Insider Trends: Insider Buying Added to with Purchase of Cel-Sci Shares
10:46AM ET 7/07/2021 MT Newswires

Geert R Kersten, Director and CEO, purchased 25,000 shares of Cel-Sci (CVM) on Jul 06, 2021, for $200,000. After the Form 4 filing with the SEC, Kersten...

Cel-Sci to Hold Investor Call Thursday to Discuss Phase 3 Head, Neck Cancer Trial Results; Shares Sink
3:11PM ET 6/30/2021 MT Newswires

Cel-Sci (CVM) said Wednesday that it will hold an investor call on Thursday at the end of its annual shareholder meeting to discuss phase 3 head and neck...

Cel-Sci's Multikine Immunotherapy Yields 14.1% Five-Year Survival Benefit in Head, Neck Cancer
10:27AM ET 6/28/2021 MT Newswires

Cel-Sci (CVM) said Monday that its Multikine immunotherapy yielded significant overall survival benefit in patients with advanced and primary squamous cell...

Cel-Sci Closes $31.7 Million Bought-Deal Offering
12:33PM ET 6/11/2021 MT Newswires

Cel-Sci (CVM) said Friday it closed its offering of 1.4 million common shares priced at $22.62 each for gross proceeds of about $31.7 million. The company...

View all Commentary and Analysis

CEL-SCI's Tough Road Ahead
12:43PM ET 8/20/2021 Seeking Alpha

CEL-SCI, Poised For Success, Is A Seriously Big Opportunity (Part II)
8:12PM ET 8/11/2021 Seeking Alpha

CEL-SCI: Pivotal Clinical Trial Results Point To Upside For Patients And Investors
1:25PM ET 7/14/2021 Seeking Alpha

Cel-Sci's Pivotal Phase 3 Results Are In: The Drama Continues
12:09PM ET 7/06/2021 Seeking Alpha

Company Profile

Business DescriptionCEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients; and CEL-2000 and CEL-4000 which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA. View company web site for more details
Address8229 Boone Boulevard
Vienna, Virginia 22182
Phone+1.703.506.9460
Number of EmployeesN/A
Recent SEC Filing01/03/20224
CEO, Chief Financial Officer, Treasurer & DirectorGeert R. Kersten
Secretary & Senior Vice President-OperationsPatricia B. Prichep
Chief Scientific OfficerEyal Talor
Vice President-Quality AssuranceWilliam Jones

Company Highlights

Price Open$5.80
Previous Close$5.82
52 Week Range$5.63 - 40.91
Market Capitalization$243.9 M
Shares Outstanding43.2 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement02/15/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.88
Beta vs. S&P 500N/A
Revenue$476.6 K
Net Profit MarginN/A
Return on Equity-83.35%

Analyst Ratings as of 05/13/2020

Buy
1
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset